ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 494

Estimation of Cost per Effectively Treated Patients with Biologic Disease Modifying Anti-Rheumatic Drugs in US Veterans with Rheumatoid Arthritis

Grant W. Cannon1, Chia-Chen Teng2, Tao He2, Jianwei Leng3, Chao-Chin Lu2, Derek Tang4, Neel Shah5, David J. Harrison4 and Brian Sauer2, 1Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT, 2Salt Lake City VA and University of Utah, Salt Lake City, UT, 3Salt Lake City VA and University of Utah, Salt Lake Citty, UT, 4Amgen Inc., Thousand Oaks, CA, 51 Amgen Center Dr, Amgen Inc., Thousand Oaks, CA

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Biologic agents, Comparative effectiveness and harms, Cost containment, economics and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Session Title: Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy: Safety of Biologics and Small Molecules in Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose:  An algorithm based on administrative claims data (in lieu of clinical measures) was validated using data from the Veteran’s Affairs (VA) Rheumatoid Arthritis (RA) Registry (VARA). It can be used to evaluate effectiveness of biologic disease modifying anti-rheumatic drugs (DMARDs) and cost per effectively treated patient.

Methods:  National VA pharmacy and administrative claims for US veterans initiating biologics (abatacept (ABA) (intravenously [IV]), adalimumab (ADA), etanercept (ETN), infliximab (INF), or rituximab (RIT)) from Jan 1, 2008 to Jan 1, 2011 were evaluated. Patients were included if they newly initiated biologic treatment ≥365days after VA enrollment and were followed for 1-year. Only biologics with ≥100 patients were evaluated.

Clinical effectiveness was estimated using an algorithm based on claims data. Patients who did not fail any of the six algorithm criteria; biologic dose escalation, switching biologics, adding a new non-biologic DMARD, receiving >1 intra-articular glucocorticoid injection, increasing glucocorticoid dose, or low treatment compliance (<80%) were categorized as effectively treated. Cost per effectively treated patient was calculated using annual medication and administration cost divided by the percentage of patients categorized as effectively treated.

Subgroup analyses stratified by age, smoking status, serologic status, and body mass index (BMI) were conducted.

Results: A total of 4,696 patients (mean age 61 years, 87% male) met all inclusion and exclusion criteria. Demographic characteristics were similar across groups. The percentage of patients categorized as effectively treated ranged from 25% to 33% and was higher for self-injected than IV biologics.  Annual cost was higher for INF and RIT compared to ABA, ADA, and ETN.

Outcomes were similar across all subgroups other than gender. Men had higher drug cost, but a higher percentage were categorized as effectively treated and the cost per effectively treated patient was lower, ($40.7k vs. $57.5k). Cost per effectively treat patient was lower for current non-smokers, patients with positive rheumatoid factor, positive anti-cyclic citrullinated peptide antibodies (aCCP), and BMI ≥30, but the differences were not statistically significant. 

Conclusion: In US veterans, the percentage of patients categorized as effectively treated using the algorithm was highest for ADA (33%) and ETN (32%) and the cost per effectively treated patient was lowest for ETN ($39.4k) and ADA ($41.5k). Male gender was associated with higher annual drug cost but lower cost per effectively treated patient.

All (n=4,696)

ABA (n=117)

ADA (n=1,989)

ETN (n=2,069)

INF (n=254)

RIT (n=267)

n (%) (95% confidence interval)

Demographics

 

 

 

 

 

 

Age (mean) at index (years)

61 (61-61)

62 (60-64)

61 (60-61)

61 (60-61)

62 (60-63)

63 (61-64)

Gender

 

 

 

 

 

 

Male

87% (86 – 88%)

80% (73-88%)

87% (85-88%)

87% (86-89%)

85% (80-89%)

85% (80-89%)

Smoking Status

 

 

 

 

 

 

Current

34% (32-35%)

28% (20-36%)

33% (31-35%)

35% (33-37%)

31% (25-37%)

31% (25-36%)

Former

37% (36-39%)

40% (31-49%)

37% (35-40%)

37% (35-39%)

35% (29-41%)

39% (33-45%)

Never

16% (15-17%)

20% (12-27%)

17% (15-18%)

16% (14-17%)

17% (12-21%)

16% (12-21%)

Unknown

13% (12-14%)

12% (6-18%)

12% (11-14%)

13% (12-14%)

17% (13-22%)

14% (10-18%)

CCP

 

 

 

 

 

 

Positive

47% (45-48%)

46% (37-55%)

47% (45-49%)

47% (45-50%)

43% (36-49%)

46% (40-52%)

Negative

20% (19-21%)

19% (12-26%)

21% (19-22%)

21% (19-23%)

17% (12-22%)

16% (12-21%)

Unknown

33% (32-34%)

35% (26-44%)

33% (30-35%)

32% 30-34%)

41% (35-47%)

37% (32-43%)

Rheumatoid Factor

 

 

 

 

 

 

Positive

61% (59-62%)

57% (48-66%)

61% (58-63%)

61% (59-63%)

51% (45-57%)

66% (60-71%)

Negative

28% (27-30%)

26% (18-34%)

572 (29%) (27-31%)

28% (26-30%)

32% (27-38%)

25% (20-30%)

Unknown

11% (10-12%)

16% (10-23%)

212 (11%) (9-12%)

11% (10-12%)

17% (12-22%)

9% (6-13%)

BMI (kg/m2)

30 (30-30)

30 (29-31)

30 (29-30)

30 (29-30)

30 (29-31)

29 (28-30)

Outcomes

 

 

 

 

 

 

Effectively treated

32% (31%-33%)

25% (17%-33%)

33% (31%-35%)

32% (30%-34%)

26% (21%-32%)

27% (22%-32%)

Annual Drug Cost ($1,000/patient)

13.5 (13.3-13.7)

13.8 (12/5-15.2)

13.9 (13.5-14.2)

12.8 (12.4-13.1)

14.4 (13.4-15.4)

15.7 (14.8-16.7)

 Cost per effectively treated patient ($1,000/patient)

42,2 (41.1-43.4)

55.8 (44.8-66.7)

41.5 (39.8-43.2)

39.4 (37.8-41.1)

54.5 (47.0-62.1)

58.32 (51.5-65.0)

Gender

Data presented with 95% CI

Male (n=4,068)

Female (n=628)

 Annual Drug Cost ($1,000/patient )

13.7 (13.4-13.9)

12.3 (11.0-12.0)

 Patients Effectively Treated

34% (32%-35%)

21% (18%-25%)

 Cost per Effectively Treated Patient ($1,000/patient)

40.7 (39.6-41.9)

57.5 (51.9-63.0)

Smoking Status

Smoker (n=1,575)

Nonsmoker (n=2,510)

 Annual Drug Cost ($1,000/patient )

13.2 (12.8-13.5)

13.7 (13.5-14.0)

 Patients Effectively Treated

29% (27%-32%)

33% (31%-35%)

 Cost per Effectively Treated Patient ($1,000/patient)

45.00 (42.8-47.3)

41.5 (40.0-43.0)

aCCP Status

Positive (n=2,199)

Negative (n=949)

 Annual Drug Cost ($1,000/patient )

13.8 (13.4-14.1)

13.4 (12.9-13.8)

 Patients Effectively Treated

33% (31%-35%)

29% (26%-32%)

 Cost per Effectively Treated Patient ($1,000/patient)

41.1 (39.5-42.7)

45.8 (42.7-48.8)

 

Rheumatoid Factor Status

Positive (n=2,843)

Negative (n=1,326)

 Annual Drug Cost ($1,000/patient )

13.5 (13.2-13.8)

13.4 (13.0-13.8)

 Patients Effectively Treated

33% (31%-35%)

30% (28%-32%)

 Cost per Effectively Treated Patient ($1,000/patient)

41.0 (39.6-42.5)

44.5 (42.1-46.9)

 

BMI (kg/m2)

≥ 30 (n=1,857)

<30 (n=2,468)

 Annual Drug Cost ($1,000/patient )

13.8 (13.4-14.1)

13.6 (13.1-13.6)

 Patients Effectively Treated

33% (31%-35%)

31% (30%-33%)

 Cost per Effectively Treated Patient ($1,000/patient)

41.9 (40.2-43.7)

42.5 (40.8-44.1)


Disclosure:

G. W. Cannon,

Amgen Inc.,

2;

C. C. Teng,

Amgen Inc.,

2;

T. He,

Amgen Inc.,

2;

J. Leng,

Amgen Inc.,

2;

C. C. Lu,

Amgen Inc.,

2;

D. Tang,

Amgen,

3,

Amgen,

1;

N. Shah,

Amgen,

3,

Amgen,

1;

D. J. Harrison,

Amgen,

3,

Amgen,

1;

B. Sauer,

Amgen Inc.,

2.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/estimation-of-cost-per-effectively-treated-patients-with-biologic-disease-modifying-anti-rheumatic-drugs-in-us-veterans-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences